It was found that CUMS treatment induced changes in the β diversity of gut microbiota and up-regulation of plasma intestinal mucosal barrier markers, ET and DAO, resulting in depression-like behavioral changes, which also supports the theory that the brain-gut axis is associated with depression. Here, DAO is linked to depressive symptom measurement.